Metabolic Disorders

United States

Metabolic Disorders

United States

Time filter

Source Type

— ReportsnReports.com latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy market (PDR) - Pipeline Review, H1 2017, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape. Browse the 16 Tables and 10 Figures, 8 Company Profiles, Spread across 59 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=983989 . Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception. Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development Acucela Inc, Aerie Pharmaceuticals Inc, Antisense Therapeutics Ltd, Icon Bioscience Inc, Ohr Pharmaceutical Inc, PanOptica Inc, Ribomic Inc, ThromboGenics NV. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=983989 Report Highlights Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Proliferative Diabetic Retinopathy Market (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 6 respectively. Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope of the report - The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/983989-proliferative-diabetic-retinopathy-pdr-pipeline-review-h1-2017.html


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017" report to their offering. Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 6 respectively. Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. For more information about this report visit http://www.researchandmarkets.com/research/ktxhwk/proliferative


— ReportsnReports.com latest Pharmaceutical and Healthcare disease pipeline guide Proliferative Diabetic Retinopathy (PDR) - Pipeline Review, H1 2017, provides an overview of the Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline landscape. Browse the 16 Tables and 10 Figures, 8 Company Profiles, Spread across 59 Pages Report Available at http://www.reportsnreports.com/contacts/discount.aspx?name=983989 . Proliferative diabetic retinopathy (PDR) is the most severe type of diabetic retinopathy. Proliferative diabetic retinopathy occurs where fragile new blood vessels form on the surface of the retina over time. These abnormal vessels can bleed or develop scar tissue causing severe loss of sight. Predisposing factors include diabetes, high blood pressure, high cholesterol, pregnancy and tobacco use. Symptoms include spots or dark strings floating in vision, vision loss, fluctuating vision, blurred vision and difficulty with color perception. Proliferative Diabetic Retinopathy (PDR) - Companies Involved in Therapeutics Development Acucela Inc, Aerie Pharmaceuticals Inc, Antisense Therapeutics Ltd, Icon Bioscience Inc, Ohr Pharmaceutical Inc, PanOptica Inc, Ribomic Inc, ThromboGenics NV. Place Order to This Report at http://www.reportsnreports.com/purchase.aspx?name=983989 . Report Highlights Pharmaceutical and Healthcare latest pipeline guide Proliferative Diabetic Retinopathy (PDR) Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Proliferative Diabetic Retinopathy Market (PDR) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Proliferative Diabetic Retinopathy (PDR) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 3, 1 and 6 respectively. Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Scope of the report - The pipeline guide provides a snapshot of the global therapeutic landscape of Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders). - The pipeline guide reviews pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Proliferative Diabetic Retinopathy (PDR) (Metabolic Disorders) About Us: ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports. For more information, please visit http://www.reportsnreports.com/reports/983989-proliferative-diabetic-retinopathy-pdr-pipeline-review-h1-2017.html


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Hyperuricemia - Pipeline Review, H1 2017" report to their offering. Pharmaceutical and Healthcare latest pipeline guide Hyperuricemia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hyperuricemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hyperuricemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hyperuricemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 3, 4 and 5 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Hyperuricemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. For more information about this report visit http://www.researchandmarkets.com/research/bmk3x6/hyperuricemia


DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Obesity - Pipeline Review, H1 2017" report to their offering. Obesity - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 1, 3, 16, 22, 129, 30 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 50 and 14 molecules, respectively. Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. For more information about this report visit http://www.researchandmarkets.com/research/t4k8ct/obesity


BOSTON & SYDNEY--(BUSINESS WIRE)--GI Dynamics®, Inc. (ASX:GID), a medical device company that has commercialized EndoBarrier® in Europe, the Middle East and South America for patients with type 2 diabetes and obesity, has announced additional members of the GI Dynamics Scientific Advisory Board (SAB), bringing together distinguished physicians and scientists specializing in endocrinology, gastroenterology and bariatric/metabolic surgery. Ricardo Cohen, MD, and Christopher Thompson, MD, MHES, have joined the GI Dynamics SAB. The GI Dynamics SAB was created to further advance the body of evidence regarding EndoBarrier and advance the state of patient care with EndoBarrier. The SAB will serve as a key resource for GI Dynamics during the Investigational Device Exemption clinical trial of EndoBarrier in the United States as well as supporting ongoing clinical studies and the commercialization process in the United Kingdom, Germany, the Middle East, and select European countries. “Dr. Cohen and Dr. Thompson will be valued members of the GI Dynamics SAB,” said Scott Schorer, GI Dynamics president and CEO. “Dr. Cohen is a leader in the type 2 diabetes and obesity field and has developed a rich history with EndoBarrier, starting with early clinical work. Dr. Thompson is a gifted gastroenterologist with deep experience in complex primary and revision procedures. He is highly experienced in new technology development and generates significant research through his clinical team,” concluded Schorer. Dr. Cohen is the director for the Center for Obesity and Diabetes at the Oswaldo Cruz German Hospital located in São Paulo, Brazil. Dr. Cohen is also the former president of the Brazilian Society of Bariatric and Metabolic Surgery, and is the current president of the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO), Latin America Chapter. Dr. Cohen has been the primary investigator (PI) for 15 studies, including two EndoBarrier studies. He has published more than 150 papers and is considered a leader in the field of surgery for patients with type 2 diabetes and non-severe obesity. “GI Dynamics with EndoBarrier has produced an excellent adjuvant tool to achieve diabetes control,” said Dr. Cohen. “I look forward to helping GI Dynamics continue to develop EndoBarrier to provide a safe and effective device in a treatment area that is growing rapidly.” Dr. Thompson is the director of Therapeutic Endoscopy at Brigham Women's Hospital and an associate professor of Medicine at Harvard Medical School in Massachusetts. He is also the current chair of the Association of Bariatric Endoscopy (ABE). He started his career in medicine after receiving his MD from Pennsylvania State University, College of Medicine in Hershey, Pennsylvania. He went on to receive his MSc in health evaluation science. Dr. Thompson has more than 200 academic publications to his name, and he has been the PI in numerous clinical trials. He is particularly well-known for his work on metabolic therapies for obesity. He is the editor of the first textbook on bariatric endoscopy, and he has trained numerous fellows in the field. “EndoBarrier is an exciting and novel technology that fills a rapidly expanding treatment gap in the management of type 2 diabetes and obesity. The GI Dynamics team has pioneered the advancement of our understanding of disease and treatment mechanisms over the past decade, and this device holds tremendous promise,” said Dr. Thompson. “I am thrilled to be joining such an accomplished group of clinicians and look forward to collaborating with them.” GI Dynamics, Inc. (ASX:GID), is the developer of EndoBarrier, the first endoscopically-delivered device therapy approved for the treatment of type 2 diabetes and obesity. EndoBarrier is approved and commercially available in multiple countries outside the United States. EndoBarrier is not approved for sale in the United States and is limited by federal law to investigational use only in the United States. Founded in 2003, GI Dynamics is headquartered in Boston, Massachusetts. For more information, please visit www.gidynamics.com. This announcement contains forward-looking statements concerning our development and commercialization plans, potential revenues and revenue growth, costs, excess inventory, profitability and financial performance, ability to obtain reimbursement for our products, clinical trials and associated regulatory submissions and approvals, the number and location of commercial centers offering the EndoBarrier, and our intellectual property position. These forward-looking statements are based on GI Dynamics’ management’s current estimates and expectations of future events as of the date of this announcement. Furthermore, the estimates are subject to several risks and uncertainties that could cause actual results to differ materially and adversely from those indicated in or implied by such forward-looking statements. These risks and uncertainties include but are not limited to, risks associated with the consequences of terminating the ENDO trial and the possibility that future clinical trials will not be successful or confirm earlier results. Further risks are associated with obtaining funding from third parties; the timing and costs of clinical trials; the timing of regulatory submissions; and the timing, receipt and maintenance of regulatory approvals. The timing and amount of other expenses and the timing and extent of third-party reimbursement risks associated with commercial product sales, including product performance, competition, risks related to market acceptance of products, intellectual-property risk; risks related to excess inventory; and risks related to assumptions regarding the size of the available market, the benefits of our products, product pricing, timing of product launches, future financial results and other factors, including those described in our filings with the U.S. Securities and Exchange Commission. Given these uncertainties, one should not place undue reliance on these forward-looking statements. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events or otherwise, unless we are required to do so by law.


WiseGuyReports.Com Publish a New Market Research Report On –“Global 3D Medical Imaging Equipment Market 2016 Share,Trend,Segmentation and Forecast to 2021”. This report studies 3D Medical Imaging Equipment in Global market, especially in North America, Europe, China, Japan, Southeast Asia and India, focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering  GE Healthcare  Hitachi Aloka Medical  Intrasense SA  Materialise NV  Philips Healthcare  Samsung Medison  Siemens Healthcare  The Esaote Group  TomTec Imaging Systems  Toshiba America Medica For more information or any query mail at [email protected] Market Segment by Regions, this report splits Global into several key Regions, with production, consumption, revenue, market share and growth rate of 3D Medical Imaging Equipment in these regions, from 2011 to 2021 (forecast), like  North America  Europe  China  Japan  Southeast Asia  India Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into  MRI  CT  Ultrasound Machines  Other 3d Medical Imaging Equipments Split by application, this report focuses on consumption, market share and growth rate of 3D Medical Imaging Equipment in each application, can be divided into  Cardiovascular  Metabolic Disorders  Central Nervous System  Oncology  General Medical Imaging  Life Science Research  Other Applications Global 3D Medical Imaging Equipment Market Research Report 2016  1 3D Medical Imaging Equipment Market Overview  1.1 Product Overview and Scope of 3D Medical Imaging Equipment  1.2 3D Medical Imaging Equipment Segment by Type  1.2.1 Global Production Market Share of 3D Medical Imaging Equipment by Type in 2015  1.2.2 MRI  1.2.3 CT  1.2.4 Ultrasound Machines  1.2.5 Other 3d Medical Imaging Equipments  1.3 3D Medical Imaging Equipment Segment by Application  1.3.1 3D Medical Imaging Equipment Consumption Market Share by Application in 2015  1.3.2 Cardiovascular  1.3.3 Metabolic Disorders  1.3.4 Central Nervous System  1.3.5 Oncology  1.3.6 General Medical Imaging  1.3.7 Life Science Research  1.3.8 Other Applications  1.4 3D Medical Imaging Equipment Market by Region  1.4.1 North America Status and Prospect (2011-2021)  1.4.2 Europe Status and Prospect (2011-2021)  1.4.3 China Status and Prospect (2011-2021)  1.4.4 Japan Status and Prospect (2011-2021)  1.4.5 Southeast Asia Status and Prospect (2011-2021)  1.4.6 India Status and Prospect (2011-2021)  1.5 Global Market Size (Value) of 3D Medical Imaging Equipment (2011-2021) 2 Global 3D Medical Imaging Equipment Market Competition by Manufacturers  2.1 Global 3D Medical Imaging Equipment Production and Share by Manufacturers (2015 and 2016)  2.2 Global 3D Medical Imaging Equipment Revenue and Share by Manufacturers (2015 and 2016)  2.3 Global 3D Medical Imaging Equipment Average Price by Manufacturers (2015 and 2016)  2.4 Manufacturers 3D Medical Imaging Equipment Manufacturing Base Distribution, Sales Area and Product Type  2.5 3D Medical Imaging Equipment Market Competitive Situation and Trends  2.5.1 3D Medical Imaging Equipment Market Concentration Rate  2.5.2 3D Medical Imaging Equipment Market Share of Top 3 and Top 5 Manufacturers  2.5.3 Mergers & Acquisitions, Expansion 7 Global 3D Medical Imaging Equipment Manufacturers Profiles/Analysis  7.1 GE Healthcare  7.1.1 Company Basic Information, Manufacturing Base and Its Competitors  7.1.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.1.2.1 Type I  7.1.2.2 Type II  7.1.3 GE Healthcare 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.1.4 Main Business/Business Overview  7.2 Hitachi Aloka Medical  7.2.1 Company Basic Information, Manufacturing Base and Its Competitors  7.2.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.2.2.1 Type I  7.2.2.2 Type II  7.2.3 Hitachi Aloka Medical 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.2.4 Main Business/Business Overview  7.3 Intrasense SA  7.3.1 Company Basic Information, Manufacturing Base and Its Competitors  7.3.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.3.2.1 Type I  7.3.2.2 Type II  7.3.3 Intrasense SA 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.3.4 Main Business/Business Overview  7.4 Materialise NV  7.4.1 Company Basic Information, Manufacturing Base and Its Competitors  7.4.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.4.2.1 Type I  7.4.2.2 Type II  7.4.3 Materialise NV 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.4.4 Main Business/Business Overview  7.5 Philips Healthcare  7.5.1 Company Basic Information, Manufacturing Base and Its Competitors  7.5.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.5.2.1 Type I  7.5.2.2 Type II  7.5.3 Philips Healthcare 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.5.4 Main Business/Business Overview  7.6 Samsung Medison  7.6.1 Company Basic Information, Manufacturing Base and Its Competitors  7.6.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.6.2.1 Type I  7.6.2.2 Type II  7.6.3 Samsung Medison 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.6.4 Main Business/Business Overview  7.7 Siemens Healthcare  7.7.1 Company Basic Information, Manufacturing Base and Its Competitors  7.7.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.7.2.1 Type I  7.7.2.2 Type II  7.7.3 Siemens Healthcare 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.7.4 Main Business/Business Overview  7.8 The Esaote Group  7.8.1 Company Basic Information, Manufacturing Base and Its Competitors  7.8.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.8.2.1 Type I  7.8.2.2 Type II  7.8.3 The Esaote Group 3D Medical Imaging Equipment Production, Revenue, Price and Gross Margin (2015 and 2016)  7.8.4 Main Business/Business Overview  7.9 TomTec Imaging Systems  7.9.1 Company Basic Information, Manufacturing Base and Its Competitors  7.9.2 3D Medical Imaging Equipment Product Type, Application and Specification  7.9.2.1 Type I  7.9.2.2 Type II For more information or any query mail at [email protected] Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports features an exhaustive list of market research reports from hundreds of publishers worldwide. We boast a database spanning virtually every market category and an even more comprehensive collection of market research reports under these categories and sub-categories.


News Article | February 23, 2017
Site: www.eurekalert.org

Is a tool that makes it possible to monitor metabolic fluxes and, in 10 minutes, provide dynamic information about a considerable number of molecules. It may be able to be used in future applications to understand the reasons why some diseases develop If we were to take photographs at the underground stations in Barcelona, we would see the number of people waiting, find out what time the rush hour takes place and deduce why some stations are busier than others. We would not know, however, if something has happened between one station and another that has led to more people being on the platforms or that might have caused delays. This is what happens when the metabolism of a cell is studied. The metabolism of a cell is like an underground network in which the chemical structures of the metabolites go from one station to another by means of biochemical transformations. Up until now, it has been possible to determine the number of many metabolites in a cell, tissue or organism, but studying their fluxes is technically much more complex and time consuming. Now, however, a group of researchers from the URV, CIBERDEM and IRB Barcelona have developed a new tool that makes this possible. The nuclear magnetic resonance (NMR) techniques used to date covered very few metabolites, researchers could take hours to measure every sample and the data were difficult to interpret. The new approach is very quick - 10 minutes per sample -, many more metabolites are obtained and the results are much easier to interpret. That is to say, the movements made by the metabolism can be determined much more easily and effectively. It is a methodology based on NMR which measures hydrogen atoms (protons) in order to indirectly determine the number of carbon atoms that are marked in the chemical structures of the metabolites. The experiment is as follows: a nutrient is marked that the cells feed on, like glucose or aminoacids, with a stable isotope. Stable isotopes such as carbon 13 are not radioactive and do not represent any danger to organisms or the people who handle the samples. The proton is measured by NMR much more quickly and sensitively than the carbon and, in this way, it is possible to study the fluxes and the transformation dynamics of these nutrients inside the cell. So far the efficacy of this new technique has been validated using human cancer cells but it is directly applicable to any biological model. Diabetes, for example, is a metabolic syndrome in which the process begins long before the levels of glucose in the blood increase, because the body uses a variety of mechanisms to ensure that the concentration of this nutrient remains stable. And high levels of glucose are only seen in the blood when the disease is at an advanced stage. The technique that has just been reported describes a new way of studying the mechanisms that cause some tissues in the organism (for example, liver or pancreas cells) not to be able to regulate levels of glucose or to become insensitive to it. That is to say, the study of metabolic fluxes helps us understand the reasons why the disease develops and the mechanism by which it does so. Therefore, it also helps in the process of diagnosis. In short, it is a methodology with great potential that practising physicians and molecular biologists will be able to use to acquire greater understanding of certain diseases. The new technique, unlike more traditional techniques, does not use radioactivity to study the metabolism. The article, which has been published in the scientific journal Angewandte Chemie, shows the results of this work on cancer cells, but the researchers are sure that glucose, aminoacids and fats marked with stable isotopes can be found in other cells and even animals. The fact that they are not radioactive makes them much easier to work with because there is no need for special laboratory conditions. In their work, the researchers have used NMR quite differently from how it has traditionally been used to study the metabolism. Maria Vinaixa, a researcher from the URV's Department of Electronic Engineering and currently carrying out research at the University of Manchester, and Oscar Yanes, a researcher from the same URV department and coordinator of the Metabolomic Platform of the Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERDEM), explain that with this methodology "we exploit to the full the power of nuclear magnetic resonance in terms of its sensitivity and coverage of the metabolism," and they believe that "it is difficult to take it any further". Now the limitation is the resonance itself. Vinaixa, M., Rodríguez, M. A., Aivio, S., Capellades, J., Gomez, J., Canyellas, N., Stracker, T. H. and Yanes, O. (2017), "Positional Enrichment by Proton Analysis (PEPA): A One-Dimensional 1H-NMR Approach for 13C Stable Isotope Tracer Studies in Metabolomics". Angew. Chem. Int. Ed. doi:10.1002/anie.201611347


Research and Markets has announced the addition of the "Global Apheresis Equipment Market Analysis & Trends - Industry Forecast to 2025" report to their offering. The Global Apheresis Equipment Market is poised to grow at a CAGR of around 12.3% over the next decade to reach approximately $4.5 billion by 2025. This industry report analyzes the market estimates and forecasts for all the given segments on global as well as regional levels presented in the research scope. The study provides historical market data for 2013, 2014 revenue estimations are presented for 2015 and forecasts from 2016 till 2025. The study focuses on market trends, leading players, supply chain trends, technological innovations, key developments, and future strategies. With comprehensive market assessment across the major geographies such as North America, Europe, Asia Pacific, Middle East, Latin America and Rest of the world the report is a valuable asset for the existing players, new entrants and the future investors. Some of the trends viewed by the market are increase in therapeutic apheresis and treatment of cancer, rise in the number of platelet donors & plasma donations, rising incidence rates of genetic disorders such as sickle cell anemia and growth Opportunities/Investment Opportunities. On the basis of technology, market is bifurcated into Membrane Filtration and Centrifugation. The Centrifugation segment is further subdivided into Continuous Flow and Intermittent Flow. Based on procedure, the market is categorized into Erythrocytapheresis, Extracorporeal Immunoadsorption (ECI), Leukapheresis, Plasmapheresis, Photopheresis, Low Density Lipoprotein (LDL) Apheresis, Plateletpheresis, Therapeutic CytApheresis Equipment and Other Procedures. Other Procedures segment is subdivided into Lipidpheresis and Lymphapheresis. Depending on application, the market is segregated into Hematology, Neurological Disorders, Renal Disorders, Metabolic Disorders, Autoimmune Disorders, Cardiovascular Disorders and Other Applications. Depending on product, the market is divided into Apheresis machine and Disposable apheresis kits - The report provides a detailed analysis on current and future market trends to identify the investment opportunities - Market forecasts till 2025, using estimated market values as the base numbers - Key market trends across the business segments, Regions and Countries - Key developments and strategies observed in the market - Market Dynamics such as Drivers, Restraints, Opportunities and other trends - Growth prospects among the emerging nations through 2025 - Market opportunities and recommendations for new investments For more information about this report visit http://www.researchandmarkets.com/research/2fd5tv/global_apheresis


TEL AVIV, Israel, March 02, 2017 (GLOBE NEWSWIRE) -- Cellect Biotechnology Ltd. (Nasdaq:APOP) (TASE:APOP), a developer of stem cells isolation technology, today announced the appointment of Dr. Michael Berelowitz to the Company’s Board of Directors. Cellect’s Board now includes seven members, five of whom are independent. Dr. Berelowitz is a former Head of Clinical Development and Medical Affairs at Pfizer and brings over 40 years of clinical, development and academic research experience. Prior to Pfizer, he spent a number of years in academia and has held appointments at the University of Chicago, University of Cincinnati College of Medicine, SUNY at Stony Brook and most recently, Mount Sinai School of Medicine. Commenting on his appointment, Dr. Berelowitz, said: “Cellect is a unique company with strong potential to become a major influencer in the future of regenerative medicine. I have always supported front-runners and I am happy to be a part of Cellect’s team on this journey.” Cellect’s Chairman of the Board, Nuriel Chirich Kasbian, said: “It is key that we construct the strongest board possible to help Cellect rise above its challenges. Dr. Berelowitz is a true asset to our company and its future growth. I welcome him to our board of directors.” Among his many accomplishments, Dr. Berelowitz has chaired the Task Force on Research of the New York State Council on Diabetes. He has also served on several editorial boards including the Journal of Clinical Endocrinology and Metabolism; Endocrinology; Reviews in Endocrine and Metabolic Disorders and Clinical Diabetes. Dr. Berelowitz has authored and co-authored more than 100 peer-reviewed journal articles and book chapters. Cellect Biotechnology is traded on both the NASDAQ and Tel Aviv Stock Exchange (NASDAQ:APOP) (NASDAQ:APOPW) (TASE:APOP). The Company has developed a breakthrough technology for the isolation of stem cells from any given tissue that aims to improve a variety of stem cells applications. The Company’s technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stems cell related treatments and procedures. Cellect’s technology is applicable to a wide variety of stem cells related treatments in regenerative medicine and that current clinical trials are aimed at the cancer treatment of bone marrow transplantations. Forward Looking Statements     This press release contains forward-looking statements about the Company’s expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. For example, forward-looking statements are used in this press release when we discuss Cellect having a strong potential to become a major influencer in the future of regenerative medicine, that Cellect has developed a breakthrough technology for the isolation of stem cells from any given tissue and that Cellect’s technology is expected to provide pharma companies, medical research centers and hospitals with the tools to rapidly isolate stem cells in quantity and quality that will allow stems cell related treatments and procedures. These forward-looking statements and their implications are based on the current expectations of the management of the Company only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; we may encounter delays or obstacles in launching and/or successfully completing our clinical trials; our products may not be approved by regulatory agencies, our technology may not be validated as we progress further and our methods may not be accepted by the scientific community; we may be unable to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties may develop with our process; our products may wind up being more expensive than we anticipate; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; our patents may not be sufficient; our products may harm recipients; changes in legislation; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in Cellect Biotechnology Ltd.'s final prospectus dated July 29, 2016 filed with the U.S. Securities and Exchange Commission, or SEC, which is available on the SEC's website, www.sec.gov. and in the Company’s period filings with the SEC and the Tel-Aviv Stock Exchange.

Loading Metabolic Disorders collaborators
Loading Metabolic Disorders collaborators